From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

“Immunotherapy and targeted therapy represent two of the biggest breakthroughs in cancer treatment in the last decade,” said co-corresponding author Ryan Corcoran, MD, ...

Dr. Manish Shah discusses the first ASCO guideline for advanced gastroesophageal cancer. He addresses biomarker testing to help guide therapy - including HER2 testing, mismatch repair testing, and ...

Researchers saw some cases where a patient’s own autoantibodies boosted likelihood of responding to checkpoint blockade.

Specifically, combination immunotherapy, in contrast to targeted therapy, produces more long-lasting tumor shrinkage, reduces the risk of disease progression in the central nervous system and ...

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2022 / 09 ...

While immunotherapy is moving into multiple realms of oncology, it still has a strong influence in the treatment of lung cancer. The PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab), ...

Over the last 15 years, systemic therapy with immunotherapy and targeted therapies have significantly improved outcomes, explained Thomas Amatruda, MD, medical oncologist, Minnesota Oncology.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the ...

“Specifically, combination immunotherapy, in contrast to targeted therapy, produces more long-lasting tumor shrinkage, reduces the risk of disease progression in the central nervous system, and ...

Neoadjuvant targeted and immunotherapy in stage 3 melanoma showed significant pathologic responses, especially in BRAF-mutated cases, with 66.7% achieving major pathologic response. The trial ...